Effect of 15d-PGJ2 on the expression of CD40 and RANTES induced by IFN-γ and TNF-α on renal tubular epithelial cells (HK-2)

American Journal of Nephrology

Volumn 26, Issue 4, 2006, Pages 356-362

  Ya, Jie Zhang ^a   Yang, Xiao ^a   Qing, Yu Kong ^a   Yun, Fang Zhang ^a   Wei, Ying Chen ^a   Xiu, Qing Dong ^a   Xiao, Yan Li ^a   Xue, Qing Yu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

CD40; Inflammation; Peroxisome proliferator activated receptor ; RANTES; Renal tubular epithelial cells

Indexed keywords

15 DEOXY 12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITROBENZANILIDE; CD40 ANTIGEN; GAMMA INTERFERON; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN DERIVATIVE; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 15 DEOXYPROSTAGLANDIN J2; 15-DEOXYPROSTAGLANDIN J2; DRUG DERIVATIVE; PROSTAGLANDIN D2;

ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; HUMAN CELL; KIDNEY TUBULE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; CELL LINE; DRUG COMBINATION; DRUG EFFECT; EPITHELIUM CELL; GENE EXPRESSION; KIDNEY TUBULE; METABOLISM;

ANTIGENS, CD40; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; INTERFERON TYPE II; KIDNEY TUBULES; PROSTAGLANDIN D2; RANTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33748681971     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094735     Document Type: Article

References (32)

1. Deckers JG, Van Der Woude FJ, van der Kooij SW, Daha MR: Synergistic effect of IL-1α, IFN-γ, and TNF-α on RANTES production by human tubular epithelial cells in vitro. J Am Soc Nephrol 1998;9:194-202.
2. Van Kooten C, Gerritsma JS, Paape ME, van Es LA, Banchereau J, Daha MR: Possible role for CD40-CD40L in the regulation of interstitial infiltration in the kidney. Kidney Int 1997;51:711-721.
3. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S: CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol 2005;16:2714-2723.
4. Datta C, Geehan D, Briscoe M, Pal S: CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol 2005;16:2714-2723.
5. Yellin MJ, D'Agati V, Parkinson G, Han AS, Szema A, Baum D, Estes D, Szabolcs M, Chess L: Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides. Arthritis Rheum 1997;40:124-134.
6. Pontrelli P, Ursi M, Ranieri E, Capobianco C, Schena FP, Gesualdo L, Grandaliano G: CD40L proinflammatory and profibrotic effects on proximal tubular epithelial cells: role of NF-κB and lyn. J Am Soc Nephrol 2006;17:627-636.
7. Kalled SL, Cutler AH, Datta SK, Thomas DW: Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function. J Immunol 1998;160:2158-2165.
8. Kairaitis L, Wang Y, Zheng L, Tay YC, Wang Y, Harris DC: Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int 2003;64:1265-1272.
9. Lloyd CM, Minto AW, Dorf ME, Proudfoot A, Wells TN, Salant DJ, Gutierrez-Ramos JC: RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997;185:1371-1380.
10. Zoja C, Donadelli R, Colleoni S, Figliuzzi M, Bonazzola S, Morigi M, Remuzzi G: Protein overload stimulates RANTES production by proximal tubular cells depending on NF-κB activation. Kidney Int 1998;53:1608-1615.
11. Danese S, de la Motte C, Reyes BM, Sans M, Levine AD, Fiocchi C: Cutting edge: T cells trigger CD40-dependent platelet activation and granular RANTES release. A novel pathway for immune response amplification. J Immunol 2004;172:2011-2015.
12. Kuroiwa T, Schlimgen R, Illei GG, McInnes IB, Boumpas DT: Distinct T cell/renal tubular epithelial cell interactions define differential chemokine production: implications for tubulointerstitial injury in chronic glomerulonephritides. J Immunol 2000;164:3323-3329.
13. Rosen ED, Spiegelman BM: PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-37734.
14. Jiang C, Ting AT, Seed B: PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998;391:82-86.
15. Marx N, Mach F, Sauty A, Leung JH, Sarafi MN, Ransohoff RM, Libby P, Plutzky J, Luster AD: Peroxisome proliferator-activated receptor-γ activators inhibit IFN-γ-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000;164:6503-6508.
16. Shiojiri T, Wada K, Nakajima A, Katayama K, Shibuya A, Kudo C, Kadowaki T, Mayumi T, Yura Y, Kamisaki Y: PPAR-γ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice. Eur J Pharmacol 2002;448:231-238.
17. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, Wu GD: A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-389.
18. 2 ameliorates experimental autoimmune encephalomyelitis. J Immunol 2002;168:2508-2515.
19. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000;43:527-550.
20. Leesnitzer LM, Parks DJ, Bledsoe RK, Cobb JE, Collins JL, Consler TG, Davis RG, Hull-Ryde EA, Lenhard JM, Patel L, Plunket KD, Shenk JL, Stimmel JB, Therapontos C, Willson TM, Blanchard SG: Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002;41:6640-6650.
21. Fu M, Zhang J, Zhu X, Myles DE, Willson TM, Liu X, Chen YE: Peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem 2001;276:45888- 45894.
22. Nicholas SB, Kawano Y, Wakino S, Collins AR, Hsueh WA: Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 2002;37:722-727.
23. Routh RE, Johnson JH, McCarthy KJ: Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int 2002;61:1365-1376.
24. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C: Agonists of peroxisome-proliferator activated receptor-γ reduce renal ischemia/reperfusion injury. Am J Nephrol 2005;23:267-276.
25. Zhang Y, Guan Y: PPAR-γ agonists and diabetic nephropathy. Curr Diab Rep 2005;5:470-475.
26. Luo Y, Liang C, Xu C, Jia Q, Huang D, Chen L, Wang K, Wu Z, Ge J: Ciglitazone inhibits oxidized-low density lipoprotein induced immune maturation of dendritic cells. J Cardiovasc Pharmacol 2004;44:381-385.
27. Pritts EA, Zhao D, Sohn SH, Chao VA, Waite LL, Taylor RN: Peroxisome proliferator-activated receptor-γ ligand inhibition of RANTES production by human endometriotic stromal cells is mediated through an upstream promoter element. Fertil Steril 2003;80:415-420.
28. Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C: Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003;85:267-273.
29. Chawla Y, Barak L, Nagy D, Liao P, Tontonoz RM: Evans, PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
30. 2 in activated murine macrophages. Mol Cell Biol 2000;20:1692-1698.
31. Rossi P, Kapahi G, Natoli T, Takahashi Y, Chen M, Santoro K, Santoro MG: Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase. Nature 2000;403:103-108.
32. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000;97:4844-4849.